<DOC>
	<DOCNO>NCT01507532</DOCNO>
	<brief_summary>Ceftazidime broad spectrum cephalosporin high activity variety Gram-negative pathogen , include Pseudomonas aeruginosa . An open-label study intravenous ceftazidime pharmacokinetics perform patient undergoing intermittent hemodialysis Northwestern Memorial Hospital determine clearance ceftazidime high flux hemodialysis .</brief_summary>
	<brief_title>Pharmacokinetic Assessment Ceftazidime Intermittent Hemodialysis Patients</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>Eligible patient male female adult ≥18 year age expect hospital stay least 48 hour , endstage renal disease receive intermittent hemodialysis least 90 day . Eligible patient additionally either central peripheral intravenous access , already prescribe ceftazidime per primary provider . Written inform consent form approve Northwestern Memorial Hospital , Northwestern University Institutional Review Board , Midwestern University Institutional Review Board complete patient prior enrollment . Patients receive one dose ceftazidime total Patients potentially alter pharmacokinetic parameter ( pregnant patient , burn patient , morbidly obese ( BMI ≥ 40 kg/m2 ) . Not meet inclusion criterion</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>